PROQR THERAPEUTICS EO-04 (0PQ) — Capital Reinvestment Ratio

Latest as of December 2023: 0.06x

PROQR THERAPEUTICS EO-04 (0PQ) has a Capital Reinvestment Ratio of 0.06x as of December 2023, meaning it reinvests 0% of its operating cash flow (€21.55 Million) in capital expenditures (€1.37 Million). See net asset quality index of PROQR THERAPEUTICS EO-04 to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.06x
Capex / Operating Cash Flow

Operating Cash Flow

€21.55 Million
EUR

Capital Expenditures

€1.37 Million
EUR

Data as of

Dec 2023
Most recent filing

PROQR THERAPEUTICS EO-04 Capital Reinvestment Ratio (2023–2023)

This chart tracks PROQR THERAPEUTICS EO-04's Capital Reinvestment Ratio across 1 annual periods. Check PROQR THERAPEUTICS EO-04 (0PQ) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for PROQR THERAPEUTICS EO-04 (2023–2023)

Year-by-year Capital Reinvestment Ratio for PROQR THERAPEUTICS EO-04 from 2023 to 2023. For live market cap and broader valuation context, see PROQR THERAPEUTICS EO-04 stock valuation.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2023 0.06x €21.55 Million €1.37 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow